And similar to PARP1 knockdown, veliparib did not synergize with ATL to inhibit the clonogenic survival of the PC-3, SW480 and A549 cancer cells (Fig. 2a, b and Fig. S3B), despite that both veliparib and olaparib efficiently suppressed PAR accumulation (Fig. 3f and Fig. S5D). The gene discussed is PARP1; the disease is cancer.